Use of iPS cells to treat spinal cord injuries

Use of iPS cells to treat spinal cord injuries

Keio University professors Hideyuki Okano (L) and Masaya Nakamura, who together lead a project to use iPS cells to treat patients with spinal cord injuries, attend a press conference in Tokyo on Feb. 18, 2019, following the Japanese health ministry's approval of a clinical study of the project. (Kyodo) ==Kyodo

  • Product Code
  • ILEA000150993
  • Registered date
  • 2019/2/18 18:25:48
  • Credit
  • Kyodo / Kyodo News Images
  • Media source
  • 2019 Kyodo News
  • Media size
  • 3857 × 2806 pixel
  • Resolution
  • 240 dpi
  • Deployment size
  • 715.50(KB)*
  • Special instruction

*File size when opened in Photoshop, etc.

Similar Images & Videos
    New coronavirus

    New coronavirus

    Japanese health minister Katsunobu Kato (L) speaks at a press conference after attending a meeting of a government panel of experts on the new coronavirus in Tokyo on Feb. 19, 2020. Seen on the right is National Institute of Infectious Diseases chief Takaji Wakita, who chaired the meeting. (Kyodo) ==Kyodo
      New coronavirus

      New coronavirus

      Officials of Japan's health ministry hold a press conference on Feb. 6, 2020, in Tokyo on the situation regarding the new coronavirus. (Kyodo) ==Kyodo
        Use of iPS cells to treat spinal cord injuries

        Use of iPS cells to treat spinal cord injuries

        Keio University professors Hideyuki Okano (L) and Masaya Nakamura, who together lead a project to use iPS cells to treat patients with spinal cord injuries, speak to reporters in Tokyo on Feb. 18, 2019, following the Japanese health ministry's approval of a clinical study of the project. (Kyodo) ==Kyodo
          Use of iPS cells to treat spinal cord injuries

          Use of iPS cells to treat spinal cord injuries

          Keio University professor Hideyuki Okano, who leads a project to use iPS cells to treat patients with spinal cord injuries, speaks at a press conference in Tokyo on Feb. 18, 2019, following the Japanese health ministry's approval of a clinical study of the project. (Kyodo) ==Kyodo
            Data altered in Japanese research for Novartis blood pressure drug

            Data altered in Japanese research for Novartis blood pressure drug

            TOKYO, Japan - Toshikazu Yoshikawa (2nd from L), president of the Kyoto Prefectural University of Medicine, and Shinji Fushiki (L), the university窶冱 vice president, bow toward the end of a press conference in Kyoto on July 11, 2013. Yoshikawa apologized as the university found that data employed in a clinical study on Novartis Pharama K.K.'s blockbuster blood pressure lowering drug Diovan were manipulated.